奈西木单抗联合顺铂治疗鳞状非小细胞肺癌及对P63、肿瘤生长作用的研究

The effect of necitumumab combined with cisplatin in the treatment of squamous non-small cell lung cancer and its effects on P63 and tumor growth

目的:研究奈西木单抗联合顺铂治疗鳞状非小细胞肺癌及对P63、肿瘤生长作用的研究.方法:将50只健康雄性小鼠分为5组,除正常组(A组)外,模型组(B组)、顺铂组(C组)、奈西木单抗组(D组)、奈西木单抗+顺铂组(E组)小鼠在静脉注射1x106/mL的鳞状细胞肺癌的细胞混悬液0.1mL,构建鳞状非小细胞肺癌模型.C组(4㎎/㎏,溶于0.5mL生理盐水,腹腔注射),D组(5㎎/㎏,溶于0.5mL生理盐水,腹腔注射),E组(5㎎/㎏+4㎎/㎏,溶于0.5mL生理盐水,腹腔注射),A和B组给予同等剂量生理盐水.观察各组小鼠治疗30天后组织中p63的表达情况,并对各组小鼠的体重、瘤重称重,计算肿瘤体积及肿瘤生长抑制率.结果:B小鼠组织中p63蛋白阳性表达的细胞数相比A组增高,经用药治疗后,C组、D组、E组p63蛋白阳性表达的细胞数均有不同程度下降,且E组的阳性表达的细胞数低于C组与D组,差异显著,具有统计学意义;B组小鼠的瘤重及体积高于C组、D组、E组,用药治疗后,C组、D组、E组小鼠的瘤重及体积均有不同程度减少,且E组减少的程度大于C组与D抗组,差异显著,具有统计学意义;E组小鼠的肿瘤生长抑制率较C组与D组高,差异显著,具有统计学差异.结论:奈西木单抗联合顺铂治疗鳞状非小细胞肺癌可降低其p63蛋白的表达,抑制肿瘤生长.

Objective To study the effect of necitumumab combined with cisplatin in the treatment of squamous non-small cell lung cancer and its effects on P63 and tumor growth.Methods 50 healthy male mice were divided into 5 groups.In addition to the normal group(A group),model group(B group),cisplatin group(C group),necitumumab group(D group),necitumumab+DDP group(E group)mice were injected with 1x106/mL squamous cells in the dorsal channel,and the cell suspension of lung cancer was 0.1mL,to Construction of squamous non-small cell lung cancer model.The C group(4 mg/kg,dissolved in 0.5mL normal saline,intraperitoneal injection),D group(5 mg/kg mAb,dissolved in 0.5mL normal saline,intraperitoneal injection),Egroup(5 mg/kg+4 mg/kg,dissolved in 0.5mL saline by intraperitoneal injection),the A group and the B group were given the same dose of normal saline.The expression of p63 in the tissues of mice in each group after 30 days was observed,the weight and tumor weight of each group were calculated,and the volume of tumor and the inhibition rate of tumor growth were calculated.Result The number of p63 protein positive cells in the B group was higher than that in the A group,after drug treatment,C group,D group,E group the number of p63 protein positive cells were decreased,and the number of p63 protein positive cells of E group was lower than that of C group and D group,significant difference was statistically significant;The tumor weight and volume of the mice in B group was higher than that of C group,D group,E group,after therapy,C group,D group,E group in mice of tumor weight and volume were decreased in different degree,and the E group reduced than C group and D group,significant difference was statistically significant;E group the inhibition rate of tumor growth increase compared with C group and D group,the difference was significant,with statistical difference.Conclusion Necitumumab combined with cisplatin can reduce the p63 protein in the treatment of squamous non-small cell lung cancer,and inhibit the growth of tumor.